Navitas Life Sciences, a TAKE Solutions Enterprise, has been named as a Leader in IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment

FRANKFURT, Germany–(BUSINESS WIRE)–Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions and a
full service Clinical, Regulatory & Safety solutions and services
provider today announced that it has been recognized as a ‘Leader’ in
the IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor
Assessment (Doc # June 2018, IDC #US42144618).


Leadership in this study is based on the breadth of life science R&D
business process outsourcing services offered, geographical footprint
and global delivery capabilities, industry-specific expertise, and
diligent vetting of customer references to examine vendor capabilities.
Navitas Life Sciences was one of nine life science R&D IT BPO vendors
selected to participate in this study based on the IDC MarketScape’s
stringent research and due diligence process.

IDC MarketScape’s vendor assessment:

“Navitas Life Sciences has extensive experience working with
pharmaceutical and biotechnology companies of all sizes and across
multiple geographies. Navitas Life Sciences is strongly differentiated
from its more traditional market competitors by its broad portfolio of
clients, ranging from small and midsize organizations to large global
pharmaceutical companies. Deep, task-level client experience over a wide
variety of specific BPO services also separates Navitas Life Sciences
from its peers in this IDC MarketScape. Relative to other vendors
discussed in this study and based on feedback from multiple customer
references, Navitas Life Sciences received high marks for its technical
skills and capabilities, deep bench and proactive approach to project
work, and ability to contribute as a strategic partner when needed.”

Ram Yeleswarapu, President, Navitas Life Sciences said, “We are
honored that our domain centricity in Life Sciences was recognized in
the form of a listing as ‘Leader’ in the prestigious IDC MarketScape
2018 Assessment”. Speaking on the latest technological innovations, he
also added, ”Artificial Intelligence (AI) will significantly transform
or impact the life sciences space. This along with robotics and
cognitive technologies is important for better outcomes, safety, and
compliance and lower costs. The use of AI will provide anticipated
savings of nearly US$ 150 billion by the mid-2020s for the United
States’ healthcare economy.”

Dr. Krishnan Rajagopalan, Chief Growth Officer, Navitas Life Sciences
said, “As part of our growth strategy, we are expanding our global
operations and services to provide a flexible and scalable partnership
model. We leverage our integrated consulting, process and technology
capabilities to deliver E2E services and outcomes across quality,
compliance, reduced time to market (TAT, Cycle time) and cost. IDC
MarketScape’s recognition is timely as we move ahead in this
transformative journey with our clients.”

Alan Louie, Research Director of IDC Health Insights’ Life Science
R&D Strategy and Technology research
, noted, “While still
somewhat smaller than its traditional IT outsourcing counterpart, BPO in
the life sciences remains an important contributor to industry success.
The scope of life science R&D BPO continues to expand as more and more
processes are operationalized and preferred IT partners are tasked with
implementing and maintaining new processes and procedures. As a result,
leading IT service providers are increasingly working as partners with
their industry sponsors to deliver operational excellence while
contributing to ongoing industry transformation that will ultimately
automate well-defined, highly repetitive tasks. While IDC continues to
expect that IT outsourcing overall will continue to grow by double
digits over the next 5–10 years, we also believe that BPO spending has
stabilized and should remain relatively constant over the near term.”

About Navitas Life Sciences

Navitas Life Sciences delivers platform-driven full-service Clinical,
Regulatory and Safety solutions and services. As the dedicated life
sciences brand of TAKE Solutions, Navitas Life Sciences operates across
North America, Europe, Asia pacific and Latin America. Navitas Life
Sciences combines the knowledge and experience of three legacy brands –
Ecron Acunova, Navitas, and Intelent. Thus, Navitas brings together the
capabilities of a full-service CRO, a technology-led life sciences
services provider, and expertise in analytics and data sciences to
address critical challenges and drive outcomes for life sciences.
Navitas has over 30 years of rich experience across 330+ phase I-IV
clinical trials, 20+ therapeutic areas, and 40+ successful GCP/non-GCP
audits. Our trial expertise is augmented by OneClinical, a platform that
delivers trial oversight, analytics, and insights to drive successful
study outcomes.

To learn more, visit www.navitaslifesciences.com.

About IDC MarketScape

IDC MarketScape vendor analysis model is designed to provide an overview
of the competitive fitness of ICT (information and communications
technology) suppliers in a given market. The research methodology
utilizes a rigorous scoring methodology based on both qualitative and
quantitative criteria that results in a single graphical illustration of
each vendor’s position within a given market. IDC MarketScape provides a
clear framework in which the product and service offerings, capabilities
and strategies, and current and future market success factors of IT and
telecommunications vendors can be meaningfully compared. The framework
also provides technology buyers with a 360 degree assessment of the
strengths and weaknesses of current and prospective vendors.

Contacts

Navitas Life Sciences
Kate Derham
kate.derham@navitaslifesciences.com
T:
+44 (0) 2392 245219